Meeting Unmet Needs

Meditrina believes that women suffering from other estrogen-dependent conditions could benefit from aromatase inhibition (AI) therapy and is working to bring new therapies to market for these new indications.  The Company’s research focuses on women’s reproductive system disorders with the goal of improving treatments for gynecologic and estrogen-dependent conditions with serious unmet needs such as abnormal uterine bleeding (AUB), ectopic pregnancy, endometriosis and uterine fibroids.